Interestingly, it has been shown that, among patients with advanced cancer, those whose tumor had a TP53 mutation had a longer progression-free survival interval on a bevacizumab-containing regimen than those whose tumor had a wild-type TP53 [45]. The gene discussed is TP53; the disease is neoplasm.